Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

John Wade

Otolaryngology Point Pleasant, WV Medical Doctor

NPI 1215066873 CMS profile 99847

2414 Jefferson Ave, Point Pleasant, WV 25550

Open in the dashboard

General payments

$2,173

123 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, John Wade of Point Pleasant, WV is reported in the CMS Open Payments database as having received $2,173 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $26 1
2022 General $498 25
2021 General $717 45
2020 General $470 28
2019 General $462 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Wade
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to John Wade were reported at $0. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year John Wade Otolaryngology median Middle half National median
2019 $462 $194 $82–$512 $163
2020 $470 $118 $42–$280 $114
2021 $717 $167 $63–$444 $132
2022 $498 $216 $84–$545 $149
2023 $26 $235 $93–$588 $160
2024 $0 $280 $111–$699 $164
2025 $0 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $635 40 payments
  2. Actelion Pharmaceuticals US, Inc. $549 24 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $281 20 payments
  4. GlaxoSmithKline, LLC. $265 17 payments
  5. OptiNose US, Inc. $128 8 payments
  6. Janssen Pharmaceuticals, Inc $120 3 payments
  7. Regeneron Healthcare Solutions, Inc. $48 3 payments
  8. Teva Pharmaceuticals USA, Inc. $32 2 payments
  9. Amgen Inc. $30 1 payment
  10. Genzyme Corporation $29 2 payments
  11. Other $56 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,173 123 payments
Products named General payments · program years 2019–2023
  1. UPTRAVI $549 24 payments
  2. SPIRIVA RESPIMAT $270 19 payments
  3. TRELEGY ELLIPTA $225 14 payments
  4. SYMBICORT $217 10 payments
  5. FASENRA Respiratory $188 9 payments
  6. BEVESPI AEROSPHERE $132 4 payments
  7. Xhance $128 8 payments
  8. FASENRA Respiratory $112 7 payments
  9. BREZTRI $96 7 payments
  10. XARELTO $81 2 payments
  11. Other $506 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record